— Research note —
5-Amino-1MQ
Small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) investigated for adipose tissue metabolism in preclinical obesity research.
5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the methylation of nicotinamide to 1-methylnicotinamide using S-adenosylmethionine as the methyl donor. Unlike most compounds in the BHC catalog, 5-Amino-1MQ is not a peptide but a low-molecular-weight quinolinium derivative; it is included in research catalogs because of its emerging utility as a tool compound for metabolic research.
NNMT has been identified through transcriptomic and proteomic studies as a gene whose expression is markedly elevated in adipose tissue of obese rodent and human subjects. The enzyme consumes both methyl donors and nicotinamide, and its activity has been proposed to drive a futile methylation cycle that depletes cellular methyl-donor pools and reduces nicotinamide available for NAD+ biosynthesis. Inhibition of NNMT in rodent models has been associated with reductions in adipose tissue mass, elevated cellular NAD+, and improved insulin sensitivity.
5-Amino-1MQ emerged from a medicinal chemistry program aimed at developing selective, cell-permeable NNMT inhibitors suitable for in vivo use. Published preclinical studies have characterized the compound's pharmacokinetics, target engagement in adipose tissue, and metabolic effects in diet-induced obese mice. The compound has become a frequently used tool in academic and industry research programs probing NNMT as a metabolic target, with related analogs advancing through earlier-stage drug discovery pipelines.
The compound is supplied here for laboratory research use only. Its utility as a chemical probe of NNMT biology is well established, while its potential for clinical translation remains a subject of ongoing investigation.
Mechanism
5-Amino-1MQ is a competitive, substrate-analog inhibitor of nicotinamide N-methyltransferase. The compound mimics the quinolinium structure of the enzyme's product 1-methylnicotinamide and binds in the active site, blocking the transfer of a methyl group from S-adenosylmethionine to nicotinamide. Inhibition is reversible and selective relative to other methyltransferases such as PRMTs and DNMTs in biochemical assays.
The downstream metabolic consequences of NNMT inhibition include preservation of cellular nicotinamide pools, which feed into the NAD+ salvage pathway via nicotinamide phosphoribosyltransferase. Researchers have observed elevations in adipocyte NAD+ following 5-Amino-1MQ treatment, with corresponding activation of sirtuin-dependent deacetylation events. Reduced consumption of S-adenosylmethionine spares this cofactor for histone and DNA methylation, potentially altering epigenetic gene regulation in adipose tissue. In murine models, these biochemical changes have been associated with increased lipolysis, reduced lipogenic gene expression, and decreased adipocyte size.
Research history
NNMT was identified as a methyltransferase in the late 1990s and characterized as a regulator of methyl-donor flux in liver and adipose tissue over the subsequent decade. The 2014 publication from the Kahn laboratory at the Joslin Diabetes Center reporting that adipose-specific NNMT knockdown protects mice from diet-induced obesity catalyzed broader interest in the enzyme as a metabolic target.
The Sciacovelli, Watson, and Tannahill groups developed early NNMT inhibitor chemistry, with 5-Amino-1MQ emerging from medicinal chemistry programs around 2018-2019 as a selective, cell-permeable lead compound. Publications characterizing the molecule's pharmacology and metabolic effects in diet-induced obese mice appeared from 2018 onward.
Subsequent research has examined NNMT inhibition in additional disease research contexts, including cancer metabolism (where elevated NNMT expression correlates with poor prognosis in several tumor types), fatty liver disease, and aging. Multiple academic and industry programs have advanced second-generation NNMT inhibitors with improved potency and pharmacokinetic profiles. The 5-Amino-1MQ scaffold continues to serve as a benchmark tool compound for target validation studies.
References
- Kraus D, et al. 2014. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. PMID: 24717514
- Neelakantan H, et al. 2018. Small molecule nicotinamide N-methyltransferase inhibitor activates methyl cycle and energy expenditure. Biochem Pharmacol. PMID: 29758185
- Neelakantan H, et al. 2019. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. PMID: 30797874
- Pissios P. 2017. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme. Trends Endocrinol Metab. PMID: 28291578
- Roberti A, et al. 2021. Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation. Mol Metab. PMID: 33186758
Do you have any questions about 5-Amino-1MQ?
Pick a path. The research assistant has the full literature context loaded.
Information presented in third-person scientific context. Research use only. Not medical advice; not for human consumption.